Vithyalakshmi Selvaraj
Psychiatry · Omaha, NENPI 1801006325
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $931,640 of the $1,155,655 with a category attached, or 80.6%. 33 manufacturers reported payments, led by AbbVie at 43.0% of the total. Among psychiatry clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,787 payments — averaging $646.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$497K
- Alkermes, Inc.$457K
- E.r. Squibb & Sons, L.L.C.$103K
- Idorsia Pharmaceuticals US Inc$48K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$41K
- Boehringer Ingelheim$2K
- plus $8K from 27 others
Across 139 payments — averaging $2798.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$196K
- E.r. Squibb & Sons, L.L.C.$126K
- Teva Pharmaceuticals USA, Inc.$60K
- Boehringer Ingelheim RCV GmbH & Co KG$6K
What the payments were for
- Consulting fees$35,5163%
- Speaking & faculty fees$931,64081%
- Travel & lodging$153,33513%
- Food & beverage$35,0113%
- Education$1530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 564 | $496,607 |
| Alkermes, Inc. | 557 | $456,569 |
| E.r. Squibb & Sons, L.L.C. | 104 | $103,485 |
| Idorsia Pharmaceuticals US Inc | 62 | $47,608 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 105 | $41,042 |
| Boehringer Ingelheim | 7 | $2,151 |
| Teva Pharmaceuticals USA, Inc. | 41 | $1,115 |
| Neurocrine Biosciences, Inc. | 30 | $1,011 |
| Harmony Biosciences LLC | 59 | $987 |
| Vanda Pharmaceuticals Inc. | 40 | $936 |
| Otsuka America Pharmaceutical, Inc. | 39 | $800 |
| Supernus Pharmaceuticals, Inc. | 28 | $654 |
| Johnson & Johnson | 24 | $462 |
| Lundbeck LLC | 24 | $417 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $243 |
| Eisai Inc. | 19 | $217 |
| Almatica Pharma LLC | 9 | $176 |
| Jazz Pharmaceuticals Inc. | 4 | $160 |
| Sunovion Pharmaceuticals Inc. | 9 | $159 |
| Axsome Therapeutics, Inc. | 8 | $125 |
| Neos Therapeutics, LP | 7 | $110 |
| Merck | 7 | $99 |
| Noven Therapeutics, LLC | 5 | $93 |
| Indivior Inc. | 4 | $73 |
| Bausch Health US, LLC | 3 | $69 |
| Avanir Pharmaceuticals, Inc. | 4 | $52 |
| Brainsway USA Inc | 2 | $52 |
| Ironshore Pharmaceuticals Inc. | 3 | $49 |
| Adlon Therapeutics L.p. | 2 | $47 |
| Neurelis, Inc. | 1 | $30 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $27 |
| Tris Pharma Inc | 1 | $16 |
| Corium, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,155,655 in reported general payments places this provider in the 95th percentile of 160 psychiatry providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 22 | $206,577 |
| AristadaAripiprazole Lauroxil | 14 | $49,568 |
| VraylarCariprazine Hcl | 34 | $49,271 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $24,796 |
| CaplytaLumateperone Tosylate | 12 | $20,721 |
| TrintellixVortioxetine Hydrobromide | 11 | $6,175 |
| Vilazodone Hcl | 54 | $5,534 |
| Clozapine | 53 | $1,878 |
| Clomipramine Hcl | 13 | $1,696 |
| Quetiapine Fumarate | 72 | $1,402 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 33 | $1,264 |
| Buspirone Hcl | 48 | $816 |
| Trazodone Hcl | 127 | $768 |
| Bupropion XlBupropion Hcl | 43 | $672 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 50 | $637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,115 | $206,57722 claims |
| Alkermes, Inc.Aristada, Lybalvi | $456,569 | $74,36530 claims |
| AbbVieVraylar | $496,607 | $49,27134 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $41,042 | $20,72112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $243 | $6,17511 claims |
| Almatica Pharma LLCSertraline Hcl | $176 | $25963 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 160 psychiatry providers in Nebraska.
Other psychiatry in Omaha
- Sarit HovavOmaha$307K
- Mary Jo HaniganOmaha$119K
- Yon ChongOmaha$59K
- Syed SattarOmaha$16K
- Michael SedlacekOmaha$15K
- Sriram RamaswamyOmaha$13K
- Elizabeth FitzpatrickOmaha$10K
- Praveen FernandesOmaha$5K
- Natalie BakerOmaha$4K
- Michael EggerOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.